Malkin D - Search Results

1

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Among authors: malkin d. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.

2

The role of tumour suppressor genes in familial cancer.

Malkin D, Friend SH. Malkin D, et al. Semin Cancer Biol. 1992 Jun;3(3):121-30. Semin Cancer Biol. 1992. PMID: 1511155 Review.

3

Screening for germ line TP53 mutations in breast cancer patients.

Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D, et al. Børresen AL, et al. Among authors: malkin d. Cancer Res. 1992 Jun 1;52(11):3234-6. Cancer Res. 1992. PMID: 1591732

4

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Malkin D, et al. Science. 1990 Nov 30;250(4985):1233-8. doi: 10.1126/science.1978757. Science. 1990. PMID: 1978757

5

High frequency of germline p53 mutations in childhood adrenocortical cancer.

Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. Wagner J, et al. Among authors: malkin d. J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10. doi: 10.1093/jnci/86.22.1707. J Natl Cancer Inst. 1994. PMID: 7966399

6

Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.

Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Malkin D, et al. Cancer Res. 1994 Apr 15;54(8):2077-9. Cancer Res. 1994. PMID: 8174107

7

Mutations of the p53 gene do not occur in testis cancer.

Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE. Peng HQ, et al. Among authors: malkin d. Cancer Res. 1993 Aug 1;53(15):3574-8. Cancer Res. 1993. PMID: 8339263

8

Germ-line mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.

Malkin D, Friend SH, Li FP, Strong LC. Malkin D, et al. N Engl J Med. 1997 Mar 6;336(10):734. doi: 10.1056/nejm199703063361018. N Engl J Med. 1997. PMID: 9045054 No abstract available.

9

Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.

Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Nichols KE, et al. Among authors: malkin d. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11219776

10

Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.

Barlow JW, Mous M, Wiley JC, Varley JM, Lozano G, Strong LC, Malkin D. Barlow JW, et al. Among authors: malkin d. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1403-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15298965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page